FLT: Measuring Tumor Cell Proliferation In Vivo With Positron Emission Tomography and 3′-Deoxy-3′-[18F]Fluorothymidine
Autor: | John R. Grierson, Alexander Salskov, Varaha S. Tammisetti, Hubert Vesselle |
---|---|
Rok vydání: | 2007 |
Předmět: |
Fluorine Radioisotopes
Pathology medicine.medical_specialty medicine.medical_treatment Tumor cells In vivo Neoplasms medicine Humans Radiology Nuclear Medicine and imaging Stage (cooking) Cell Proliferation Chemotherapy medicine.diagnostic_test business.industry Cancer medicine.disease Dideoxynucleosides 18f fluorothymidine medicine.anatomical_structure Positron emission tomography Positron-Emission Tomography cardiovascular system Cancer research sense organs Bone marrow Radiopharmaceuticals business circulatory and respiratory physiology |
Zdroj: | Seminars in Nuclear Medicine. 37:429-439 |
ISSN: | 0001-2998 |
Popis: | Positron emission tomography (PET) using the radiotracer 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) can image cellular proliferation in human cancers in vivo. FLT uptake has been shown to correlate with pathology-based proliferation measurements, including the Ki-67 score, in a variety of human cancers. Unlike pathology-based measurements, imaging-based methods, including FLT-PET, are noninvasive, easily repeatable, and less prone to sampling errors. FLT-PET may therefore be a useful tool for assessing tumor aggressiveness, predicting outcome, planning therapy, or monitoring response to treatment. Three recent clinical studies have reported that FLT-PET can accurately predict response very early after the initiation of chemotherapy. Especially with the advent of cytostatic chemotherapy agents, methods of biologically assessing a tumor's response will take on increasing importance, since changes in tumor size will not always be expected. To date, most studies of FLT-PET have focused on validating it as a means of quantifying cellular proliferation and testing its ability to accurately stage cancer. In some settings, FLT-PET has shown greater specificity for cancer than (18)F-fluorodeoxyglucose (FDG)-PET, which can show false-positive uptake in areas of infection or inflammation. However, because of FLT's lower overall uptake and higher background activity in liver and bone marrow, FLT-PET should not be considered a potential replacement for staging by FLT-PET. Instead, FLT-PET should be considered a powerful addition to FDG-PET, providing additional diagnostic specificity and important biological information that could be useful in predicting prognosis, planning treatment, and monitoring response. |
Databáze: | OpenAIRE |
Externí odkaz: |